Enfusion, Inc.

Enfusion, Inc.

ENFN
Enfusion, Inc.US flagNew York Stock Exchange
10.76
USD
-0.04
- -
1.02BMarket Cap
Enfusion, Inc.
ENFN
(New York Stock Exchange)

Recent

price

10.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
TTM
FRC
0.92
1.24
1.34
1.76
1.98
- -
2.19
Revenue per Share
0.2
0.06
-1.9
-0.09
0.07
- -
0.03
Basic EPS, GAAP
0.12
-0.05
-0.08
0.12
0.24
- -
0.34
Free Cash Flow per Basic Share
0.17
0.07
0.04
- -
- -
- -
- -
Dividend per Share
-1.84
-3.64
-2.06
-2.09
-1.96
- -
-1.85
Book Value per Share
-1.84
-3.65
1.17
1.21
0.88
- -
1.08
Tangible Book Value per Share
64
64
83
85
88
- -
92
Basic Weighted Avg Shares
59
80
112
150
175
202
202
Sales/Revenue/Turnover
23.5
7.63
-246.99
-7.96
6.85
3.05
3.05
Operating Margin (%)
1
2
4
6
10
12
12
Depreciation Expense
13
4
-158
-8
6
3
3
Net Income, GAAP
3.7
9.64
- -
- -
19.43
47.02
47.02
Effective Tax Rate (%)
21.44
5.1
-141.73
-5.09
3.45
1.4
1.4
Profit Margin (%)
8
18
82
79
50
66
66
Working Capital
27
96
- -
3
11
14
14
LT Debt
-118
-234
97
103
77
100
100
Total Equity
- -
- -
- -
- -
9.45
3.05
3.05
Return on Invested Capital (%)
- -
-4.95
- -
- -
-2.1
-1.35
-1.35
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
13
15
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
93
95
Market Capitalization
763
866
948

Working Capital

FRC

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
74
85
94
Cash, Cash Equivalents & STI
34
48
54
Accounts Receivable, Net
34
32
32
Inventories
- -
- -
- -
Total Current Liabilities
18
24
27
Payables & Accruals
4
6
7
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-6.81%
28.47%
Free Cash Flow
- -
-31.69%
46.58%
Net Income, GAAP
- -
-878.68%
-53.15%
Sales/Revenue/Turnover
- -
28.28%
15.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
34
37
39
41
150
2023
41
43
44
46
175
2024
48
49
51
53
202

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.09
-0.03
0.02
- -
-0.09
2023
0.03
0.01
0.02
- -
0.07
2024
-0.01
0.02
0.02
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Enfusion, now operating as a Clearwater Analytics company, delivers comprehensive software-as-a-service solutions to the global investment management sector, spanning the United States, Europe, the Middle East, Africa, and the Asia Pacific region. The firm’s integrated, cloud-native platform is engineered to unify front, middle, and back-office operations, providing investment managers with real-time, data-driven intelligence. Central to its offerings is the Portfolio Management System, which generates an immediate investment book of record, offering valuation and risk assessment tools for chief investment officers and portfolio managers to analyze aggregated or granular portfolio data. Additionally, the platform features an Order and Execution Management System, enabling portfolio managers, traders, and compliance personnel to digitally transmit trade orders across diverse asset classes, manage transactions efficiently, and systematically enforce trading rules and internal compliance. Enfusion also provides an Accounting/General Ledger System, establishing a live accounting book of record that automates the posting of general ledger entries for all cash and securities activities, benefiting chief financial officers, chief operating officers, accountants, and operations teams. Complementing this is the Enfusion Analytics System, empowering CIOs, portfolio managers, traders, and analysts to examine portfolios across various time horizons and produce automated, customized visual reports for both internal and external stakeholders. The company further extends its capabilities through technology-driven and managed services. Originally founded in 1997, Enfusion, Inc. completed its acquisition by Clearwater Analytics in April 2025, a move valued at approximately $1.5 billion, creating a unified front-to-back platform for the investment management industry. It maintains its headquarters in Chicago, Illinois.

Company News

APIChat
  • Clearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful Growth

  • Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy

  • Clearwater Analytics Finalizes Acquisition of Enfusion

  • Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration

  • Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration

  • ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN

  • Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates

  • Enfusion Announces Fourth Quarter and Full Year 2024 Results

  • Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion

  • ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders

  • Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock

  • Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

  • Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Shareholders to Inquire about Securities Investigation

  • Bronstein, Gewirtz & Grossman, LLC Is Investigating Enfusion, Inc. (ENFN) And Encourages Investors to Connect

  • Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Stockholders to Inquire about Securities Investigation

  • Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Enfusion, Inc. (ENFN) and Encourages Investors to Learn More About the Investigation

  • Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

  • The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Enfusion, Inc. For Securities Fraud

  • Enfusion, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

  • Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Stockholders to Reach Out